GIP(3-30)NH2 + GLP-1(7-36)NH2

GIP(3-30)NH2 + GLP-1(7-36)NH2 is a combination of two synthetic peptide fragments that target the incretin hormone pathways. GIP(3-30)NH2 is a truncated form of glucose-dependent insulinotropic polypeptide (GIP), typically acting as a GIP receptor antagonist, while GLP-1(7-36)NH2 is the active form of glucagon-like peptide 1 (GLP‑1), functioning as an agonist at the GLP‑1 receptor. This combination is used primarily in research to study the physiological and pharmacological effects of modulating both incretin pathways simultaneously. The dual modulation allows for investigation into glucose metabolism, appetite regulation, and weight management by either stimulating or inhibiting these receptors. While dual agonists like tirzepatide are approved for type 2 diabetes and obesity[6][5][4], this specific combination—using an antagonist for GIP and an agonist for GLP‑1—is not marketed but serves as a valuable tool in metabolic research.